Tag Archives: ARQL

Hot Biotech Stocks To Watch Right Now

Elliott Management is offering $160 in cash per share for athenahealth (NASDAQ:ATHN), a software company that’s reshaping the market for electronic health records. The deal may not get done, though, because athenahealth’s CEO, Jonathan Bush, has a long-term vision for athenahealth that may not jibe with Elliott Management’s plans. Could a friendly suitor emerge as a white knight that acquires athenahealth?

A market in big need of disruption

Most healthcare providers have replaced their endless rows of file cabinets with digital health records. But the health-records market is fragmented, so the digital records available to most patients are far from comprehensive.

IMAGE SOURCE: GETTY IMAGES.

Unfortunately, incomplete or inconsistent patient histories could be undermining providers’ treatment decisions, and causing unnecessary expenses because of duplicate testing. On a grander scale, the gaps in patient data are frustrating efforts by healthcare providers and payers to leverage artificial intelligence to crunch healthcare data in ways that can improve treatment for life-threatening conditions, such as diabetes, cancer, and heart disease.

Hot Biotech Stocks To Watch Right Now: Biogen Idec Inc(BIIB)

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include the AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); TYSABRI to treat relapsing MS; FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. Biogen Idec Inc.?s products under Phase III consist of PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; Long-lasting factor IX and VIII fusion protein for the treatment of hemophilia B; GA101, a monoclonal antibody for t he treatment of chronic lymphocytic leukemia and NHL; and Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis. The company?s Phase I clinical trial products include Anti-LINGO for use in multiple sclerosis, Neublastin for use in neuropathic pain, CD40L for use in systemic lupus erythematosus, ANTI-TWAEK humanized monoclonal antibody for TWEAK, and BIIB037 for use in Alzheimer’s disease; and Phase II clinical trial product comprises OCRELIZUMAB, a humanized monoclonal antibody for treating CD20. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; Swedish Orphan Biovitrum AB; Abbott Biotherapeutics Corp; and Vernalis plc. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.

Advisors’ Opinion:

  • [By ]

    Just last Thursday, March 21, Biogen (Nasdaq: BIIB) and its partner, Japanese biopharmaceutical company Eisai (OTC: ESALY), said that their experimental Alzheimer’s therapy, which at that time was at the second stage of clinical trials, was a bust. BIIB dropped 29.2% on the day, and ESALY by 35% on the same day.

  • [By Chris Hill]

    In this episode ofMotley Fool Money, host Chris Hill and analysts Emily Flippen, Jim Mueller, and Jason Moser hit on some of the biggest recent news in the market. Disney (NYSE:DIS)finishes up its merger with Fox, and it’s ready to take on a crowded streaming space. CVS Health(NYSE:CVS) diversifies into CBD lotion. Levi Strauss(NYSE:LEVI) enters the public markets with a bafflingly high market cap, while Nike (NYSE:NKE)sells off on higher-than-expected revenue and profits. Biogen’s (NASDAQ:BIIB) biggest trial bombs, and the stock tanks along with it. Papa John’s(NASDAQ:PZZA) welcomes Shaq into its board of directors. And, as always, the analysts share some stocks on their radar. Plus, stay tuned for an interview with Lake House Capital’s Joe Magyer about investing in Australia — the biggest trends, biggest worries, and some Aussie picks to add to your watch list.

  • [By Garrett Baldwin]

    Nike Inc. (NYSE: NKE) will lead a busy day of earnings reports. The firm expects that its year-over-year sales will have increased by 7%. The company’s stock slumped in February after Duke basketball player Zion Williamson was hurt blowing out his sneaker in the first minute of a major contest against North Carolina. Expect analysts to ask a lot of questions about Nike’s expectations for global economic growth and its exposure to a weakening Chinese economy.
    Stocks to Watch Today: BIIB, BA, LEVI
    Shares of Biogen Inc.(NASDAQ: BIIB) plunged more than 25% after the company announced a major setback for a key Alzheimer’s drug. The biotech giant announced that its experimental drug “aducanumab” is unlikely to be effective for mass deployment and that it will halt its research. One analyst described this as a “transformative failure for Biogen’s pipeline.” This is a massive setback for one of the top biotech companies in the world. Shares of Boeing Co. (NYSE: BA) are off again Thursday on news that the investigation into its 737 Max jets has expanded. According to reports, the FBI has now joined a federal investigation into the certification process for the jet. The Department of Transportation launched an audit of the Federal Aviation Administration’s approval of the jet, which received certification two years ago. Boeing and the FAA have faced global scrutiny over two fatal crashes involving the 737 Max jet series and news of previous pilot complaints about the planes. Levi Strauss & Co. (NYSE: LEVI) will return to the public markets for the first time in 34 years. The iconic apparel company will launch its IPO today with a price of $17 per share. That would set the company’s market capitalization at $6.6 billion. Look for other earnings reports from Canadian Solar Inc. (NASDAQ: CSIQ), Cintas Corp. (NASDAQ: CTAS), CNOOC Ltd. (NYSE: CEO), Conagra Brands Inc. (NYSE: CAG), Darden Restaurants Inc. (NYSE: DRI), and Lands’ End Inc. (NYSE: LE).
    Public Law 92-

Hot Biotech Stocks To Watch Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its core product programs under clinical or pre-clinical development include ALN-TTR, a Phase I clinical trial program for the treatment of transthyretin-mediated amyloidosis; ALN-APC, a Phase I clinical trial program for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN, a pre-clinical development for the treatment of refractory anemia; and ALN-TMP, a pre-clinical development for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The company?s partner-based programs comprise ALN-RSV01, a Phase II clinical trial program for the treatment of respiratory syncytial virus infection; ALN-VSP, a Phase I clinical trial completed program for the treatment of liver cancers; and ALN-HTT, a pre-clinical development for the treatment of Huntington?s disease. It has strategic alliances with Novartis Pharma AG; F. Hoffmann-La Roche Ltd; Takeda Pharmaceutical Company Limited; Isis Pharmaceuticals, Inc.; Medtronic Inc.; Kyowa Hakko Kirin Co., Ltd.; and Cubist Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Cory Renauer]

    Staying on top of every new drugmaker takes a lot more time than you probably have. That said,Alnylam Pharmaceuticals (NASDAQ:ALNY)andPfizer (NYSE:PFE) shareholders want to keep their eyes on young Eidos and its lead candidate. Here’s why.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) updated investors last month on how the launch of Onpattro, its first drug that was approved to treat transthyretin-mediated amyloidosis (ATTR), was going at the J.P. Morgan Healthcare Conference.

Hot Biotech Stocks To Watch Right Now: ArQule Inc.(ARQL)

ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product ARQ 197 is non-adenosine triphosphate competitive inhibitor of the c-Met receptor tyrosine kinase, which is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in non-small cell lung cancer, c-Met-associated soft tissue sarcomas, pancreatic adenocarcinoma, hepatocellular carcinoma, germ cell tumors, and colorectal cancer. The company is also developing ARQ 621, a Phase I program focused on inhibition of the Eg5 kinesin spindle protein. Its clinical stage products include ARQ 501, ARQ 761, and ARQ 171, which are designed to kill cancer cells selectively while sparing normal cells through the direct activation of DNA damage response/checkpoint pathways. In addition, the company involves in pre-clinical development o f B-RAF and AKIP Kinase inhibitors. The company has collaborations with Kyowa Hakko Kirin Co., Ltd. and Daiichi Sankyo Co., Ltd. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.

Advisors’ Opinion:

  • [By Cory Renauer]

    It isn’t unusual for oncology stocks to double in a single day after a company announces clinical trial results. Arqule (NASDAQ:ARQL) stands out among its peers because it notched a 67% gain after reporting a partial remission for just one leukemia patient.

  • [By Motley Fool Transcribers]

    Arqule Inc (NASDAQ:ARQL)Q42018 Earnings Conference CallMarch 07, 2019, 9:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Dan Caplinger]

    Thursday was another down day for the stock market, with new pressure coming from international moves on the macroeconomic front. The European Central Bank signaled that it was ready to provide more accommodative monetary policy, reversing a previous tightening stance and showing its concerns about the prospects for economic growth in the region. Yet favorable earnings reports continued lifting shares of certain individual companies. Rosetta Stone (NYSE:RST), ArQule (NASDAQ:ARQL), and Fly Leasing (NYSE:FLY) were among the top performers. Here’s why they did so well.

Hot Biotech Stocks To Watch Right Now: Amgen Inc.(AMGN)

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body?s response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Advisors’ Opinion:

  • [By Motley Fool Staff]

    Every so often on Rule Breaker Investing, Motley Fool co-founder David Gardner shares a five-stock sampler — five active recommendations in either Rule Breakers or Stock Advisor that are poised for great things. This week: five healthcare companies that are innovating treatments and drugs that are making the world healthier. Learn more about Amgen (NASDAQ:AMGN), bluebird bio (NASDAQ:BLUE), Editas Medicine (NASDAQ:EDIT), Illumina (NASDAQ:ILMN), and Vertex Pharmaceuticals (NASDAQ:VRTX) and why you should add these exciting and inspiring stocks to your watch list.

  • [By ]

    Even though ABBV has more than 100 patents covering Humira, and despite its 2017 patent win over Amgen (Nasdaq: AMGN) requiring AMGN to wait until 2023 before issuing its own copy of Humira, the battle for generic Humira isn’t over.

Best Safest Stocks To Buy Right Now

Carillon Tower Advisers Inc. increased its holdings in Lennar Co. (NYSE:LEN) by 1.6% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 471,785 shares of the construction company’s stock after buying an additional 7,607 shares during the period. Carillon Tower Advisers Inc.’s holdings in Lennar were worth $24,768,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Commonwealth Equity Services LLC increased its stake in Lennar by 7.8% in the second quarter. Commonwealth Equity Services LLC now owns 13,363 shares of the construction company’s stock valued at $702,000 after acquiring an additional 966 shares during the last quarter. Advisor Partners LLC increased its stake in Lennar by 20.5% in the first quarter. Advisor Partners LLC now owns 6,284 shares of the construction company’s stock valued at $370,000 after acquiring an additional 1,069 shares during the last quarter. Trust Co increased its stake in Lennar by 15.4% in the first quarter. Trust Co now owns 8,349 shares of the construction company’s stock valued at $492,000 after acquiring an additional 1,115 shares during the last quarter. Oppenheimer & Co. Inc. increased its stake in Lennar by 15.2% in the first quarter. Oppenheimer & Co. Inc. now owns 8,604 shares of the construction company’s stock valued at $507,000 after acquiring an additional 1,138 shares during the last quarter. Finally, LPL Financial LLC increased its stake in Lennar by 8.7% in the first quarter. LPL Financial LLC now owns 14,515 shares of the construction company’s stock valued at $856,000 after acquiring an additional 1,157 shares during the last quarter. Institutional investors own 85.59% of the company’s stock.

Best Safest Stocks To Buy Right Now: S&P GSCI(GD)

General Dynamics Corporation, an aerospace and defense company, provides business aviation; combat vehicles, weapons systems, and munitions; military and commercial shipbuilding; and communications and information technology products and services worldwide. Its Aerospace group designs, manufactures, and outfits various large and mid-cabin business-jet aircraft; provides maintenance, repair work, fixed-based operations, and aircraft management services; and performs aircraft completions for aircraft. The company?s Combat Systems group offers tracked and wheeled military vehicles, weapons systems, and munitions. Its product lines include wheeled combat and tactical vehicles; battle tanks and infantry vehicles; munitions and propellant; rockets and gun systems; and axle and drivetrain components and aftermarket parts. This group also manufactures and supplies engineered axles, suspensions, and brakes for heavy-load vehicles for military and commercial customers. The company Advisors’ Opinion:

  • [By Lou Whiteman]

    There’s more at stake for Huntington Ingalls and fellow shipbuilder General Dynamics (NYSE:GD) beyond the $6.5 billion in lost refueling revenue. A modern aircraft carrier does not sail alone but rather relies on a large number of escorts and affiliated ships that also need to be acquired and staffed. There is also the expense of finding pilots for the large number of planes that are housed on a carrier.

  • [By Logan Wallace]

    WARNING: “General Dynamics Co. (GD) Stake Lowered by ETRADE Capital Management LLC” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at www.tickerreport.com/banking-finance/4200512/general-dynamics-co-gd-stake-lowered-by-etrade-capital-management-llc.html.

Best Safest Stocks To Buy Right Now: Dynagas LNG Partners LP(DLNG)

Dynagas LNG Partners LP, through its subsidiaries, operates in the seaborne transportation industry worldwide. The company owns and operates liquefied natural gas (LNG) vessels. As of January 21, 2016, its fleet consisted of six LNG carriers, with an aggregate carrying capacity of approximately 913,980 cubic meters. Dynagas GP LLC serves as the general partner of Dynagas LNG Partners LP. The company was founded in 2013 and is based in Monaco.

Advisors’ Opinion:

  • [By Ethan Ryder]

    Dynagas LNG Partners (NYSE:DLNG) will post its quarterly earnings results after the market closes on Wednesday, May 16th. Analysts expect Dynagas LNG Partners to post earnings of $0.17 per share for the quarter.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Valeritas Holdings Inc (NASDAQ: VLRX) fell 25.9 percent to $1.89 in pre-market trading. Valeritas priced its 13.7 million share offering at $1.75 per share.
    Zealand Pharma A/S (NASDAQ: ZEAL) fell 6.5 percent to $15.30 in pre-market trading after rising 9.80 percent on Monday.
    Dynagas LNG Partners LP (NYSE: DLNG) fell 5.1 percent to $9.00 in pre-market trading after slipping 1.15 percent on Monday.
    Incyte Corporation (NASDAQ: INCY) fell 5 percent to $64.80 in pre-market trading. Lilly and Incyte disclosed that the FDA Advisory Committee recommended approval of baricitinib 2mg, but not 4mg, for the treatment of moderately-to-severely active RAI.
    Casa Systems, Inc. (NASDAQ: CASA) fell 4.7 percent to $28.40 in pre-market trading after announcing a 7.35 million share common stock offering.
    Assured Guaranty Ltd. (NYSE: AGO) shares fell 4.5 percent to $34.30 in pre-market trading. The founder and president of Greenlight Capital talked about a short idea in Assured Guaranty, saying pre-tax income is likely to “collapse.” He also highlighted Assured Guaranty insured $12.2 billion in below-investment grade bonds.
    The St. Joe Company (NYSE: JOE) shares fell 4 percent to $17.30 in pre-market trading.
    Masco Corporation (NYSE: MAS) shares fell 3.4 percent to $38.10 in pre-market trading

  • [By Lisa Levin]

    Dynagas LNG Partners LP (NYSE: DLNG) shares dropped 12 percent to $9.30 after the company lowered its quarterly distribution to $0.25 per common unit from $0.4225 per common unit.

Best Safest Stocks To Buy Right Now: Constellation Brands Inc(STZ)

Constellation Brands, Inc., incorporated on December 4, 1972, is an international beverage alcohol company. The Company is a producer and marketer of beer and wine the United States and Canada. The Company’s segments include Beer, Wine and Spirits, and Corporate Operations and Other. The Company’s wine portfolio is complemented by select spirits brands and other select beverage alcohol products. It is a multi-category supplier (beer, wine and spirits) of beverage alcohol in the United States.

The Company owns principal facilities, including the Nava Brewery in Nava, Coahuila, Mexico; the glass production plant in Nava, Coahuila, Mexico; wineries in California, which include the Woodbridge Winery in Acampo and the Mission Bell winery in Madera; the Canandaigua winery in Canandaigua, New York, and the distillery in Lethbridge, Alberta, Canada. It operates over four facilities in the San Diego, California area that produce its Ballast Point brand, including Miramar, which serves as the primary production site for the brand. In the United States, the Company operates over 20 wineries using varieties of grapes grown in the Napa, Sonoma, Monterey and San Joaquin regions of California. It also operates approximately eight wineries in Canada, over four wineries in New Zealand and approximately five wineries in Italy. The Company’s Canadian whisky requirements are produced and aged at its Canadian distillery in Lethbridge, Alberta.

Beer

The Company sells a number of brands in the import and craft beer categories. Within the imported beer category, the Company has rights to import, market and sell its Mexican Beer Brands in over 50 states of the United States, which include Corona Extra, Corona Light, Modelo Especial, Pacifico, Negra Modelo and Victoria. It also includes Modelo Especial Chelada, which is a blend of beer with flavors of tomato, salt and lime. Its craft beer products are primarily sold under the Ballast Point brand. Ballast Point produces over 40 different s! tyles of beer.

Wine and Spirits

The Company is a producer and marketer of wine. It sells a number of wine brands across various categories, including table wine, sparkling wine and dessert wine, and across all price points, such as popular, premium and luxury categories. The Company owns, leases or has interests in approximately 13,300 acres of vineyards in California (the United States), over 5,800 acres of vineyards in New Zealand, approximately 1,700 acres of vineyards in Canada and over 900 acres of vineyards in Italy.

The Company’s wine produced in the United States is primarily marketed domestically and in Canada. Wine produced in Canada is primarily marketed domestically. Wine produced in New Zealand and Italy is primarily marketed in the United States and Canada. In addition, the Company exports its wine products to other major world markets. Some of its wine and spirits brands sold in the United States include Arbor Mist, Black Box, Blackstone, Clos du Bois, Estancia, Franciscan Estate, Inniskillin, Kim Crawford, Mark West, Mount Veeder, Nobilo, Ravenswood, Rex Goliath, Robert Mondavi, Ruffino, Simi, Toasted Head, Wild Horse, Black Velvet Canadian Whisky and SVEDKA Vodka. In its spirits business, SVEDKA Vodka is imported from Sweden and is the imported vodka brand in the United States.

The Company competes with Anheuser-Busch InBev, MillerCoors, Heineken, Pabst Brewing Company, The Boston Beer Company, E&J Gallo Winery, The Wine Group, Trinchero Family Estates, Treasury Wine Estates, Ste. Michelle Wine Estates, Deutsch Family Wine & Spirits, Jackson Family Wines, Andrew Peller, Kruger Wines and Spirits, Diageo, Beam Suntory, Brown-Forman, Sazerac Company and Pernod Ricard.

Advisors’ Opinion:

  • [By Motley Fool Transcribers]

    Constellation Brands Inc (NYSE:STZ)Q42019 Earnings Conference CallApril 04, 2019, 10:30 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Garrett Baldwin]

    The Trump administration is back under pressure with Democrats in the House. According to reports, House Democrats have asked the IRS to give them six years of the president’s personal tax returns and corporate returns. Massachusetts Rep. Richard Neal, the head of the leader of the House Ways and Means Committee, has made the first request for tax returns of a sitting U.S. president in 45 years. The IRS has reportedly not replied to Neal’s demand, which has a set deadline of April 10. The request is likely set to unleash a legal battle between Democrats and the White House through 2020. Investors must pay close attention to a more important development. Last Friday (March 29), H.R. 1595, better known as the Secure and Fair Enforcement (SAFE) Banking Act, passed the House Committee on Financial Services in a 45-15 vote. The bill will now head to the floor of the House of Representatives, where it is widely expected to pass. Turns out, everyone in Congress wants to be involved. The bill now has a staggering 152 cosponsors. You couldn’t even get 152 congressmen to agree on a bill that endorses sunshine. Now, investors are poised to make huge gains on this development. Money Morning Director of Cannabis Investing Research Greg Miller tells you how to profit today.
    Stocks to Watch Today: STZ, TSLA, LYFT
    Shares of Constellation Brands Inc. (NYSE: STZ) are on the move as investors digest the firm’s earnings report. The earnings report comes just as the company announced plans to sell roughly 30 wine brands to Gallo in a deal worth about $1.7 billion. Don’t expect analysts to spend too much time exploring the fine ink on that deal. Instead, expect a lot of focus on the firm’s recent shift into the cannabis business and questions about its profit growth.

    5G Revolution: This breakthrough technology is expected to unleash $12 TRILLION in new wealth… and one $6 stock could be better positioned than any other to skyrocket. Learn more.

  • [By Todd Campbell]

    Beer, wine, and spirits company Constellation Brands (NYSE:STZ) owns a 38% stake in Canopy Growth, and it estimates the global, legal market for marijuana could exceed $200 billion in 15 years. Recognizing that consumer products, including beverages, that use marijuana’s chemical cannabinoids, including CBD, as ingredients will represent a big portion of future sales, Aurora Cannabis’ decision to bring Nelson Peltz on as an advisor is wise.

Best Safest Stocks To Buy Right Now: ArQule Inc.(ARQL)

ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product ARQ 197 is non-adenosine triphosphate competitive inhibitor of the c-Met receptor tyrosine kinase, which is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in non-small cell lung cancer, c-Met-associated soft tissue sarcomas, pancreatic adenocarcinoma, hepatocellular carcinoma, germ cell tumors, and colorectal cancer. The company is also developing ARQ 621, a Phase I program focused on inhibition of the Eg5 kinesin spindle protein. Its clinical stage products include ARQ 501, ARQ 761, and ARQ 171, which are designed to kill cancer cells selectively while sparing normal cells through the direct activation of DNA damage response/checkpoint pathways. In addition, the company involves in pre-clinical development o f B-RAF and AKIP Kinase inhibitors. The company has collaborations with Kyowa Hakko Kirin Co., Ltd. and Daiichi Sankyo Co., Ltd. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.

Advisors’ Opinion:

  • [By Cory Renauer]

    It isn’t unusual for oncology stocks to double in a single day after a company announces clinical trial results. Arqule (NASDAQ:ARQL) stands out among its peers because it notched a 67% gain after reporting a partial remission for just one leukemia patient.

  • [By Motley Fool Transcribers]

    Arqule Inc (NASDAQ:ARQL)Q42018 Earnings Conference CallMarch 07, 2019, 9:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Best Safest Stocks To Buy Right Now: Warren Resources Inc.(WRES)

Warren Resources, Inc., an independent energy company, engages in the exploration, development, and production of onshore crude oil and gas reserves in the United States. It primarily explores for oil reserves in the Wilmington field in California; and natural gas in the Washakie Basin in Wyoming. The company was founded in 1990 and is headquartered in New York, New York.

Advisors’ Opinion:

  • [By Shane Hupp]

    Northland Securities restated their corporate rating on shares of W Resources (LON:WRES) in a research note issued to investors on Wednesday.

    Shares of LON WRES opened at GBX 0.43 ($0.01) on Wednesday. W Resources has a 52 week low of GBX 0.25 ($0.00) and a 52 week high of GBX 0.72 ($0.01).

Best Safest Stocks To Buy Right Now: Paylocity Holding Corporation(PCTY)

We are a cloud-based provider of payroll and human capital management, or HCM, software solutions for medium-sized organizations, which we define as those having between 20 and 1,000 employees. Our comprehensive and easy-to-use solutions enable our clients to manage their workforces more effectively. As of June 30, 2016, we served approximately 12,500 clients across the U.S., which on average had over 100 employees. Our solutions help drive strategic human capital decision-making and improve employee engagement by enhancing the human resource, payroll and finance capabilities of our clients.

Our multi-tenant software platform is highly configurable and includes a unified suite of payroll and HCM applications, such as time and labor tracking, benefits and talent management.   Advisors’ Opinion:

  • [By Ethan Ryder]

    ILLEGAL ACTIVITY WARNING: “Paylocity Holding Corp (PCTY) Shares Bought by OLD National Bancorp IN” was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at www.tickerreport.com/banking-finance/4141322/paylocity-holding-corp-pcty-shares-bought-by-old-national-bancorp-in.html.

  • [By Motley Fool Transcribers]

    Paylocity Holding Corp (NASDAQ:PCTY)Q22019 Earnings Conference CallFeb. 06, 2019, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Paylocity (PCTY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com